Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial

在加纳和孟加拉国，一项随机、对照、开放标签、非劣效性3期临床试验评估了由大肠杆菌生产的二价人乳头瘤病毒疫苗（Cecolin）在9-14岁女孩中的免疫原性和安全性。